You are here


Bumper crop of new drugs fails to lift big pharma R&D returns

Projected returns at 12 top drugmakers falls to an 8-year low of only 3.2%: Deloitte


SO FAR this year, the US Food and Drug Administration, gatekeeper to the world's biggest drugs market, has approved 41 novel drugs compared with 22 for the whole of 2016.

It is shaping up to be a bumper year for drug approvals, with US officials clearing twice as many novel...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to